Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Venclyxto“
Suchtreffer
Begriffe & Kennungen
Venclyxto · 4.8 · 18 In the M14-358 study, discontinuations due to adverse reactions occurred in 26% of patients treated with th
Eintrag öffnenVenclyxto · 4.8 · 19 The incidence of laboratory TLS was 0.3% (1/323) in the single-arm phase 2 CAPTIVATE study, reported in one
Eintrag öffnenVenclyxto · 4.8 · 20 percent experienced dose interruption, 4% had dose reduction and 1 patient (0.3%) discontinued venetoclax d
Eintrag öffnenVenclyxto · 4.8 · AMPLIFY When venetoclax is administered in combination with acalabrutinib with or without obinutuzumab, refer
Eintrag öffnenVenclyxto · 4.8 · Acute myeloid leukaemia
Eintrag öffnenVenclyxto · 4.8 · Chronic lymphocytic leukaemia
Eintrag öffnenVenclyxto · 4.8 · Description of selected adverse reactions
Eintrag öffnenVenclyxto · 4.8 · Discontinuation and dose reductions due to adverse reactions
Eintrag öffnenVenclyxto · 4.8 · Discontinuations due to adverse reactions in the AMPLIFY study occurred in 8% of patients treated with venetoc
Eintrag öffnenVenclyxto · 4.8 · Discontinuations due to adverse reactions occurred in 16% of patients treated with venetoclax in combination w
Eintrag öffnenVenclyxto · 4.8 · Dosage reductions due to adverse reactions in the AMPLIFY study occurred in 14% of patients treated with venet
Eintrag öffnenVenclyxto · 4.8 · Dosage reductions due to adverse reactions occurred in 21% of patients treated with venetoclax in combination
Eintrag öffnenVenclyxto · 4.8 · Dose interruptions due to adverse reactions in the AMPLIFY study occurred in 50% of patients treated with vene
Eintrag öffnenVenclyxto · 4.8 · Dose interruptions due to adverse reactions occurred in 74% of patients treated with the combination of veneto
Eintrag öffnenVenclyxto · 4.8 · During post-marketing surveillance, TLS, including fatal events, has been reported after a single 20 mg dose o
Eintrag öffnenVenclyxto · 4.8 · General disorders Fatigue Very common and administration Asthenia site conditions Fatigue Common Asthenia
Eintrag öffnenVenclyxto · 4.8 · General disorders Very common Fatigue and administration site conditions Common Fatigue Blood creatinine Inves
Eintrag öffnenVenclyxto · 4.8 · In 168 patients with CLL starting with a daily dose of 20 mg and increasing over 5 weeks to a daily dose of 40
Eintrag öffnenVenclyxto · 4.8 · In M14-358 study, no events of laboratory or clinical TLS were reported with venetoclax in combination with de
Eintrag öffnenVenclyxto · 4.8 · In the AMPLIFY study, neutropenia/neutrophil count decreased/febrile neutropenia (all grades) was reported in
Eintrag öffnen